Compared with ICI group, an increasing trend of TD (OR 2.640, 95% CI [2.328-2.995]) was found in TKI+ICI group, while a lower risk of GMD (OR 0.388, 95% CI [0.328-0.459]) and PD (OR 0.312, 95% CI [0.255-0.383]) was observed in TKI+ICI group.
← all excerpts
7626 Endocrine Adverse Reactions Of Tyrosine Kinase Inhibitors In Combination With Immune Checkpoint Inhibitors: A Retrospective Analysis Using The US FDA Adverse Event Reporting System
1
—
—